IVBM All Coverage

Oncology specialist Jasmine Eugene, PharmD, explains how pharmacists practicing at the top of their license help close cancer care gaps amid provider shortages.

Kavita Nair, PhD, FAAN, discusses academic medical centers' unique role in diagnosing and managing neurodegenerative diseases.

Jasmine Eugene, PharmD, explains how pharmacists practicing at the top of their license improve rural oncology access and ease physician workload.

Clark Alsfeld, MD, discusses how telemedicine, pharmacists, and evolving policies help overcome financial and geographic barriers in oncology care.

Danielle Roman, PharmD, BCOP, discusses the challenges of accessing genomic test results and managing prior authorization in patient care for breast cancer.

Broader eligibility, real-world data, and community partnerships are expanding access to CAR T-cell therapy.

Oncology care advances target social determinants of health through AI, patient education, and community engagement.

Michael Hassett, MD, MPH, discusses the rise of oral therapeutics in breast cancer care, emphasizing patient support, education, and overcoming financial barriers for better outcomes.

Experts discuss the evolution of cancer care, emphasizing value-based approaches, precision oncology, and the importance of multidisciplinary collaboration for improved patient outcomes.

Ken Cohen, MD, FACP, discusses how new cognitive assessment tools are improving Alzheimer disease diagnosis.

Susan Escudier, MD, FACP, of Texas Oncology, suggests actionable insights to improve equitable access to patient cancer care

Incorporating tools that gauge social determinants of health can improve patient access to cancer care, explained Susan Escudier, MD.

Ken Cohen, MD, FACP, discusses how clinicians can support patients after a cognitive screening to identify meaningful next steps.

Susan Escudier, MD, discusses the practical implications of financial barriers for patients with cancer accessing oncology care.

Kavita Nair, PhD, FAAN, discusses the rising global burden of neurodegenerative diseases.

Andrew Wolf, MD, discusses the growing costs, treatment advances, and geographic disparities in multiple sclerosis care.

Tara Carlisle, MD, PhD, University of Colorado, discusses how coordinated care efforts and frequent safety monitoring are transforming early Alzheimer disease management.

Ken Cohen, MD, FACP, discusses the importance of expanding cognitive screening for seniors.

Experts discuss the importance of initiating blinatumomab treatment for acute lymphoid leukemia in academic centers for optimal patient care.

Kelley L. Julian, PharmD, BCOP, discusses optimizing myeloma care, addressing barriers in access to intravenous immunoglobulin and innovative therapies at Huntsman Cancer Institute.

Clinician's role in breast cancer care and access with reproductive and urinary oncologist Lakshminarayanan Nandagopal, MD

Advancements in breast cancer care and treatments with reproductive and urinary oncologist Lakshminarayanan Nandagopal, MD.

Oranus Mohammadi, MD, outlines how antibody-drug conjugates are transforming breast cancer treatment across subtypes and discusses her approach to sequencing high-cost targeted therapies within payer and clinical practice constraints.

Matias Sanchez, MD, a hematologist-oncologist at University of Illinois Health, discussed the latest advancements in value-based multiple myeloma care, including minimal residual disease strategies and innovative targeted therapies.

Oranus Mohammadi, MD, discusses the emerging applications of circulating tumor DNA (ctDNA) in breast cancer care and emphasizes the importance of clear communication to help patients navigate uncertain or anxiety-provoking biomarker test results.

Joanne Mortimer, MD, FACP, FASCO, discusses the practical applications and limitations of circulating tumor DNA (ctDNA) testing in breast cancer, highlighting its role in guiding targeted therapy, challenges in patient communication and payer coverage, and unique barriers for male patients.

Jorge Nieva, MD, explores the challenges of translating biomarker testing into treatment decisions for non–small cell lung cancer (NSCLC), the role of repeat testing in detecting resistance mutations, and the importance of equitable access to molecular diagnostics in value-based care settings.

Jorge Nieva, MD, highlights the critical role of molecular testing in non–small cell lung cancer (NSCLC) care, while addressing barriers such as limited tissue samples, delayed turnaround times, and the need for faster, more accessible diagnostic technologies.